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Abstract
We use a simple SIR-like epidemic model which integrates known age-contact patterns for the United
States to model the effect of age-targeted mitigation strategies for a COVID-19-like epidemic. We find
that, among strategies which end with population immunity, strict age-targeted mitigation strategies
have the potential to greatly reduce mortalities and ICU utilization for natural parameter choices.
1 Introduction
There is currently a shortage of publicly available COVID-19 modeling which considers strict but age-targeted
mitigation strategies—in particular, strategies which may divide the labor force into low-risk and high-risk
groups.
In this paper, we use a simple age-sensitive SIR (Susceptible, Infected, Removed) model integrating
known age-interaction contact patterns to examine the potential effects of age-heterogeneous mitigations
on an epidemic in a COVID-19-like parameter regime. Our goal is to demonstrate the qualitative point
that for an epidemic with COVID-19-like parameters, age-sensitive mitigations can result in considerably
less mortality and ICU usage than homogeneous mitigations, among strategies which end with population
immunity.
We model mitigations which result in a 70% reduction in transmission rates among all of the population
except for a relaxed group. In our models, natural transmission rates correspond to an R0 of 2.7. (In
Section 5, we consider other parameter choices.) We consider relaxation strategies based on age thresholds;
for example, relaxing restrictions on all people under 50. Because people of different ages often live in the
same household, and because other risk factors might also be used to inform mitigation efforts, we consider
strategies where only some fraction of people under the age threshold are subject to relaxed restrictions.
Related work has in the context of MERS can be found in [5], and for H1N1 swine flu in [1].
2 The model
We use a simple SIR-like model acting on n age groups. Let I(t), S(t), R(t),M(t) be vector-valued functions
of time, each vector of length n, where the jth coordinate of each of I(t), S(t), R(t), and M(t), respectively,
denote the the number of people in the jth age group who are infected, susceptible, recovered, or deceased
at time t.
We let C be the age-group contact matrix. This is a symmetric matrix describing the frequency of
transmission events between age groups, relative to the products of the population sizes. (In particular, even
if the sizes of age groups vary, C would be a constant matrix if we assumed people were equally likely to
have have transmission interactions regardless of age.) The constant α is the total recovery/removal rate,
and the vector δ = (δ1, . . . , δn) gives the death rate for each group separately.
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Given a vector v, we let Mv denote the diagonal matrix whose ith diagonal entry is the ith coordinate
of v.
The dynamics of the model are captured by the following vector differential equations:
dI(t)
dt
= I(t)CMS(t) · 1
m
− αI(t) (1)
dS(t)
dt
= −I(t)CMS(t) · 1
m
(2)
dR(t)
dt
= (α1− δ) I(t) (3)
dM(t)
dt
= δ  I(t). (4)
Here  denotes coordinate-wise multiplication, and m is the total population.
When modeling mitigation strategies, the contact matrix C will be modified. In the absence of mitigations,
we could simply set C to be a scalar multiple of the all-1’s matrix J (with the scalar set to reproduce the
desired R0 value). More realistically, we can incorporate known patterns of inter-age-group interactions.
To do this, we use contact matrices generated by [6], see Section 3; these are are extrapolations based on
contact patterns originally measured by recording contact patterns for a large sample of people in European
countries. In this manuscript, we use the contact matrices from [6] generated for the United States.
One feature of using a non-constant contact matrix C is that the steady state proportions of a growing
epidemic are no longer uniform among the age-groups in the population. For example, if we model a situation
where we begin with 105 infections in a much larger population, we do not expect those to be uniformly
distributed by age, but instead distributed in a way which depends on C.
To understand the dependence on C, let γ denote a vector of length n whose proportions represent infected
fractions of each age group in the early growth of an epidemic (i.e., in the period where R0 is often measured
in the field). We call this the early-stable proportion vector. We let ρ = (ρ1, . . . , ρn) be the vector giving the
fraction of the total population within each age group. If the relative magnitudes of the coordinates of γ
are in steady-state (that is, if γ will grow in all coordinates uniformly), this means from (1), that for some
constant K we have that
γCMρ − αγ = Kγ
In particular, γ is a positive eigenvector of the positive matrix CMρ. Such an eigenvector exists and is
unique, by the Perron–Frobenius theorem. We let λ1 denote its eigenvalue, which is the (unique) largest
eigenvalue of CMρ.
To tie our model to empirical estimates of R0 for COVID-19, we wish to compute a scaling factor β for
the matrix C which gives rise to an exponential growth in ∑nj=1 Ij(t) which corresponds to the empirical
R0 value computed early in an epidemic (before a substantial fraction of the population is infected), given
an infection distributed according to the early-stable proportion vector γ. For the vector γ, multiplication
by CMρ is equivalent to multiplication by the eigenvalue λ1, thus for an infected population with age
distribution proportional to γ, and writing I for∑nj=1 Ij , the dynamics near t = 0 reduce (1) to a standard
single population SIR model with the infected population governed by the equation
dI(t)
dt
=
λ1
m
I(t)− αI(t).
In particular, we see that R0 =
λ1
α , and thus the correct scaling for the contact matrix C to replicate the
known R0 value is that which ensures that
λ1 = R0 · α.
We use the recovery rate α = 1/14, corresponding to a 2-week recovery period. The mortality rate and
rate of ICU admissions per infection are taken from Report 9 of the team at Imperial College London [4];
we use the data from their Table 3, which we reproduce here:
2
Age-group
% symptomatic cases
req. hospitalisation
% hospitalised cases
req. critical care
IFR
0 to 9 0.1% 5.0% 0.002%
10 to 19 0.3% 5.0% 0.006%
20 to 29 1.2% 5.0% 0.03%
30 to 39 3.2% 5.0% 0.08%
40 to 49 4.9% 6.3% 0.15%
50 to 59 10.2% 12.2% 0.60%
60 to 69 16.6% 27.4% 2.2%
70 to 79 24.3% 43.2% 5.1%
80+ 27.3% 70.9% 9.3%
Note that we do not apply a correction for asymptomatic cases, which may make our analysis conservative
(pessimistic). Comparable (but not identical) estimates may be found from other sources. For example, see
[3], Table S2.
Source code for our model can be found at the entry for this paper at http://math.cmu.edu/~wes/pub.html.
3 The contact matrix
Figure 1: The contact matrix we use, derived from the contact matrix generated in [6] for the United States.
We use the contact matrix generated for the United States in [6]. Note that matrices provided in [6] are
actually quite asymmetric, because they correspond to frequencies of interactions, which are affected also
by the proportions of the populations belonging to different age group. (In particular, if all groups were
equally likely to interact, [6] would report a contact matrix in which each row was equal to the population-
proportion vector for the age groups). The dynamics we describe in (1), etc., already account for the
proportion of the susceptible population which belongs to each age group, thus we process the contact
matrix by dividing column by the proportion of the population in the corresponding age group. This results
in a nearly symmetric matrix, which we symmetrize by taking the average of pairs of elements reflected
across the diagonal. We also bin the 5-year age groups used in [6] to correspond to our 10-year age groups,
and treat the 80+ and 70-79 groups identically for the purposes of the contact matrix, since [6] does not
provide separate contact data for the 80+ age group.
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Note that one could use location-specific contact matrices (for work interactions, home interactions, etc),
but we have eschewed this choice at this stage since doing so requires a model of how these different types
of interactions coordinate to contribute to empirically observed R0 values.
4 Results
Our simulations all begin from an initial infection affecting 100, 000 individuals (distributed proportional
to the early-stable proportion vector) in an otherwise fully susceptible population of size roughly 3 × 108.
In all of our scenarios, we assume that normal transmission levels are linearly resumed between the 9- and
15-month marks from the start of the simulation.
As a first example, Figure 2A models the epidemic in the absence of any mitigations at all. Figure 2B
models the epidemic in the presence of strict mitigations which, as in all our scenarios, are gradually relaxed
between the 9- and 12-month marks. Each figure shows the size of the infected population over time, and
the ICU utilization over time, by age group. Each figure caption indicates Total Mortalities (TM) from the
scenario. Note the light gray shading in the figures modeling mitigations serve as a reminder that normal
transmission is linearly resumed between the 9- and 15- month marks.
4.1 The power of mitigations and natural heterogeneity
In all our scenarios, we assume that transmission rates linearly resume between the 9 month and 15 month
points.
Figure 3A shows the outcome of optimal homogeneous measures. That is, among all transmission re-
ductions which could be applied equally to the all age groups and then gradually resumed as we assume,
this is the choice of transmission reduction which minimizes deaths. Transmission levels in this scenario are
reduced by 40% for all age groups in this scenario. Note that this results in a reduction of mortalities by
nearly 50%.
Figure 3B shows the outcome of the same mitigations ignoring the role of natural contact patterns in
the population. In particular, for this scenario we have assumed a counterfactual where the likelihood of
two people of different ages interacting is determined just by the relative sizes of the populations of the
age-groups; this corresponds to a constant C matrix. We see 2.5 times more mortalities in this scenario,
demonstrating the power of natural population heterogeneity to reduce infection mortality for COVID-19.
(The optimum choice for transmission is roughly the same for the uniform contact matrix.)
In all our figures, the scale ICU utilization is shown rescaled by a factor of 10,000total population . In other
words, units for the ICU utilization figures is the ICU capacity—per 10,000 people—required to support
ICU admissions at that level. The red line shows a nominal capacity level of 3.47 beds per 10,000 people.
4.2 Age-targeted mitigations
For our age-targeted mitigations, we consider relaxing mitigations just on those under 40, just on those
under 50, and just on those under 60.
Since it is natural to expect targeted mitigations to be based on household-level of risks, because of
cohabitation of younger and older adults, we consider, in each case, a scenario where only 2/3 of the younger
population is subject to normal transmission levels.
In each of these scenarios, depicted in Figures 4, 5, and 6, we assume that the relaxed population is
subject to normal transmission levels, while transmission to, from, and within the rest of the population is
depressed by 70% from normal levels. (Results for other choices for these and other constants are discussed
in Section 5.)
What we see in Figures 4, 5, and 6 is that age-targeting has the potential to greatly reduce total mortalities
compared with optimum choices for homogeneous measures. At the same time, we see that the best strategies
for age-targeting are sensitive to the fraction of the younger population which can be released. In general,
if too few people are released initially, a second wave occurs when transmission levels return to normal.
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Figure 2: A: No mitigations. (TM: 15 · 105). B: Containment followed by resumption in transmission levels
between 9 and 15 months (TM: 15 · 105).
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Figure 3: A: Optimum homogeneous mitigations. TM: 7.8 · 105. B: Homogeneous measures without the
contact matrix. TM: 19.14 · 105.
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Conversely, if too many are released, ICU utilization is high in the first wave. Thus the optimum choice for
the age cutoff depends on the fraction of people we expect below the age cutoff to actually be released.
5 Sensitivity of analysis
In Section 4.2 we presented scenarios of age-targeted mitigations where R0 = 2.7 and transmission levels for
the groups subject to mitigations are reduced by 70%. In Figures 8, 9, 10, 11, 12, 13, 14, 15, 16 we show
scenarios where R0 is 2.4, 2.7, or 3.0, and the transmission reduction for the group subject to mitigations is
90%, 70%, or 50%. (We refer to these as very strict mitigations, strict mitigations, and moderate mitigations.)
Note that the panel for R0 = 2.7 with strict mitigations (70% reduction) includes the scenarios discussed in
Section 4.2.
In each of these figure panels, scenarios where peak ICU utilization does not exceed the nominal ICU
capacity by more than 50% are highlighted. Note that this includes some scenarios which exhibit a large
second wave and thus exhibit many mortalities.
The figures for these scenarios all plot 36 months of simulation. In a few cases, a small but non-negligible
part of the second wave occurs past this point. Mortality and ICU utilization for each scenario is summarized
in Table 1; this data is based on a 10 year simulation period, to capture second waves extending beyond 36
months.
6 Age-specific mortality impact
It might be natural to suspect that age-specific strategies are simply trading mortalities in one group for
mortalities in another. However, we find in our models that age-targeted restrictions can dramatically reduce
mortalities among older populations with very small impacts on mortality in younger populations; see Figure
7. In particular, because of the effect age-targeted measures can have on ICU over-utilization (whose impact
on mortality we have not modeled), it is quite possible that well-calibrated age-targeted mitigations could
improve typical outcomes for all age groups.
7 Discussion and caveats
We have considered a model of age-heterogeneous transmission and mitigation in a COVID-19-like epidemic,
which is simple but also tied to current estimates of both disease parameters and U.S.-specific contact
patterns. We find that age-targeted mitigations can have a dramatic effect both on mortality and ICU
utilization. However, we also find that to be successful, age-targeted mitigations may have to be strict. Our
scenarios modeling moderate mitigations on the restricted group (shown in Figures 10, 13, and 16) fare quite
poorly (see also Table 1).
Importantly, we find that while relatively good strategies exist in a range of scenarios, so long as miti-
gations on restricted groups can be strict or very strict, the precise choices which minimize ICU utilization
and deaths are sensitive—for example, to the fraction of younger people which will actually be released from
mitigations.
We also find that if only moderate mitigations are possible on the population subject to mitigations, then
the discrete set of age-targeted mitigations we considered fared poorly.
We view our modeling as demonstrating a qualitative point: strict age-targeted mitigations can have
a powerful effect on mortality and ICU utilization. We expect that public policy motivated by this kind
of finding would have to be responsive; for example, by relaxing restrictions on larger and large groups
conservatively, while monitoring the progress of the epidemic.
Note in Table 1, for every R0 value, there are heterogeneous strategies that outperform the optimal
homogeneous strategies. There are also heterogeneous strategies that do worse, sometimes much worse.
These poor-performing strategies fall into one of two types:
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Figure 4: A: 2/3 of people of under 39 released at normal levels (TM: 9.0 · 105). B: All of people of under
39 released at normal levels (TM: 3.9 · 105).
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Figure 5: A: 2/3 under 49 released at normal levels (TM: 6.0 · 105). B: All under 49 released at normal
levels (TM: 5.0 · 105).
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• Those with too large a relaxed population, so that the initial epidemic is not sufficiently constrained,
and
• Those with too small a relaxed population, so that when transmission rates resume, a second wave
results (which disproportionately effects the older population).
The simple lessons for policy are twofold: first, initial relaxations must be responsive to conditions
on the ground, e.g., through monitoring of ICU utilization. Second, the return to normal must also
proceed cautiously and, ideally, be informed by data on the size of the infected population. Although we
have considered simple 2-stage strategies here, it would be natural to consider implementing policies with
more stages, as a way of proceeding cautiously.
Any predictive model is an oversimplification of the real world whose predictions depend on parameter
values whose true values will only be known after-the-fact. The model we employ is particularly simple, and
while this simplicity can be an asset when demonstrating qualitative phenomena, it also presents obvious
limitations. For example:
• We do not model seasonality, since the effects of seasonality on COVID-19 remain unsettled. Seasonal
forcing could mean, for example, that after relaxing restrictions on some group, they may have to be
reinstated as transmission rates increase.
• While we do use (simple) models of known age-group contact patterns, we don’t model the effects of
specific mitigations on those patterns; for example, we don’t evaluate the specific effects of things like
closing schools. We also don’t attempt to model the different effects of mitigations on within-home and
out-of-home contact patterns, since the ways these each contribute to empirically observed R0 values
is complicated.
• There is still considerable uncertainty regarding basic parameters of COVID-19 such as its transmis-
sibility, the infection mortality rate, and the ICU admission rate. While we have relied on expert
choices for the parameters we have used, all quantitative findings we make (such as ICU admissions)
are sensitive to these choices.
On the other hand, there are ways in which our analysis has been conservative. For example:
• When modeling homogeneous mitigation strategies in Figure 2, we allow ourselves complete freedom
to choose an effective R0 value resulting from mitigations. On the other hand, for our examples
of heterogeneous mitigation strategies, we have tied our hands considerably more. We simply allow
ourselves to choose which age group, in intervals of 10, to release to normal transmission levels—we
have just a few discrete options to choose from. In particular, if were allowed ourselves to combine
mild mitigations on the relaxed group with strong mitigations on the rest, we would be able to achieve
fewer mortalities and ICU admissions. Note that many of our age-targeted mitigation scenarios exhibit
epidemics which end well before the 9-month mark; these curves have room to be flattened.
• We have considered scenarios where all the younger age group will be able to have relaxed transmission
rates, because of cohabitation with older household members, or because of risk factors other than age.
This can make our analysis worse, by making the average age of the required immunity herd. However,
we have not taken advantage of a presumed benefit that this would confer: if effective risk-models
incorporating factors beyond age could be deployed, it is plausible that the ICU admission rate for the
relaxed groups could be decreased.
• We have not modeled flexibility in ICU capacity.
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R0 strategy supression relaxed ages fraction mortalities peak.ICU
2.4 homogeneous optimal NA NA 6.79 4.64
2.4 heterogeneous 90% up to 39 0.67 9.26 6.82
2.4 heterogeneous 90% up to 49 0.67 6.45 2.52
2.4 heterogeneous 90% up to 59 0.67 4.51 2.19
2.4 heterogeneous 90% up to 69 0.67 5.29 3.51
2.4 heterogeneous 90% up to 39 1 1.35 1.69
2.4 heterogeneous 90% up to 49 1 2.21 3.22
2.4 heterogeneous 90% up to 59 1 4.23 6.95
2.4 heterogeneous 90% up to 69 1 7.46 12.05
2.4 heterogeneous 70% up to 39 0.67 6.96 1.95
2.4 heterogeneous 70% up to 49 0.67 3.94 3.09
2.4 heterogeneous 70% up to 59 0.67 4.51 4.56
2.4 heterogeneous 70% up to 69 0.67 5.66 5.82
2.4 heterogeneous 70% up to 39 1 3.89 4.78
2.4 heterogeneous 70% up to 49 1 4.96 7.01
2.4 heterogeneous 70% up to 59 1 6.66 10.42
2.4 heterogeneous 70% up to 69 1 9.20 14.55
2.4 heterogeneous 50% up to 39 0.67 6.09 5.81
2.4 heterogeneous 50% up to 49 0.67 6.70 7.13
2.4 heterogeneous 50% up to 59 0.67 7.48 8.52
2.4 heterogeneous 50% up to 69 0.67 8.35 9.62
2.4 heterogeneous 50% up to 39 1 7.09 9.00
2.4 heterogeneous 50% up to 49 1 7.92 11.28
2.4 heterogeneous 50% up to 59 1 9.12 14.05
2.4 heterogeneous 50% up to 69 1 10.92 17.07
2.7 homogeneous optimal NA NA 7.43 5.35
2.7 heterogeneous 90% up to 39 0.67 11.19 10.13
2.7 heterogeneous 90% up to 49 0.67 8.62 5.01
2.7 heterogeneous 90% up to 59 0.67 6.57 2.19
2.7 heterogeneous 90% up to 69 0.67 7.15 3.51
2.7 heterogeneous 90% up to 39 1 2.27 1.69
2.7 heterogeneous 90% up to 49 1 2.21 3.22
2.7 heterogeneous 90% up to 59 1 4.23 6.95
2.7 heterogeneous 90% up to 69 1 7.46 12.05
2.7 heterogeneous 70% up to 39 0.67 9.00 3.89
2.7 heterogeneous 70% up to 49 0.67 6.09 3.09
2.7 heterogeneous 70% up to 59 0.67 4.54 4.56
2.7 heterogeneous 70% up to 69 0.67 5.68 5.82
2.7 heterogeneous 70% up to 39 1 3.89 4.78
2.7 heterogeneous 70% up to 49 1 4.96 7.01
2.7 heterogeneous 70% up to 59 1 6.66 10.42
2.7 heterogeneous 70% up to 69 1 9.20 14.55
2.7 heterogeneous 50% up to 39 0.67 6.11 5.81
2.7 heterogeneous 50% up to 49 0.67 6.70 7.13
2.7 heterogeneous 50% up to 59 0.67 7.48 8.52
2.7 heterogeneous 50% up to 69 0.67 8.35 9.62
2.7 heterogeneous 50% up to 39 1 7.09 9.00
2.7 heterogeneous 50% up to 49 1 7.92 11.28
2.7 heterogeneous 50% up to 59 1 9.12 14.05
2.7 heterogeneous 50% up to 69 1 10.92 17.07
3 homogeneous optimal NA NA 8.02 6.83
3 heterogeneous 90% up to 39 0.67 12.80 13.21
3 heterogeneous 90% up to 49 0.67 10.52 7.87
3 heterogeneous 90% up to 59 0.67 8.43 3.70
3 heterogeneous 90% up to 69 0.67 8.85 3.51
3 heterogeneous 90% up to 39 1 6.13 1.74
3 heterogeneous 90% up to 49 1 2.21 3.22
3 heterogeneous 90% up to 59 1 4.23 6.95
3 heterogeneous 90% up to 69 1 7.46 12.05
3 heterogeneous 70% up to 39 0.67 10.78 6.29
3 heterogeneous 70% up to 49 0.67 8.03 3.09
3 heterogeneous 70% up to 59 0.67 6.00 4.56
3 heterogeneous 70% up to 69 0.67 6.57 5.82
3 heterogeneous 70% up to 39 1 3.89 4.78
3 heterogeneous 70% up to 49 1 4.96 7.01
3 heterogeneous 70% up to 59 1 6.66 10.42
3 heterogeneous 70% up to 69 1 9.20 14.55
3 heterogeneous 50% up to 39 0.67 6.76 5.81
3 heterogeneous 50% up to 49 0.67 6.70 7.13
3 heterogeneous 50% up to 59 0.67 7.48 8.52
3 heterogeneous 50% up to 69 0.67 8.35 9.62
3 heterogeneous 50% up to 39 1 7.09 9.00
3 heterogeneous 50% up to 49 1 7.92 11.28
3 heterogeneous 50% up to 59 1 9.12 14.05
3 heterogeneous 50% up to 69 1 10.92 17.07
Table 1: Mortalities and ICU admissions by scenario. Like homogeneous strategies, heterogeneous strategies
can perform suboptimally because they are too relaxed and allow too large of an epidemic in the mitigation
period, or too strict and invite a second wave in the hypothetical resumption normal transmission levels.
Highlighted rows are scenarios which have lower mortalities than the optimal homogeneous measures for the
same R0.
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Figure 6: A: 2/3 under 59 released at normal levels (TM: 4.53 · 105). B: All under 59 released at normal
levels (TM: 6.66 · 105).
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Figure 7: Impact on mortalities by age group. The bottom row of this table shows mortalities in each age
group for the optimum homogeneous mitigations scenario, as a fraction of the total population of the age
group. Each other row corresponds to a scenario discussed in Section 4.2. The values in the cells in these
rows show the difference in the mortality rate for each age group for the given scenario, compared with the
optimum homogeneous scenario.
11
age bracket 80+70−79
60−69
50−59
40−49
30−39
20−29
10−19
0−9
Infe
ctions
ICU
0 3 6 9 12 15 18 21 24 27 30 33 36
0e+00
1e+07
2e+07
3e+07
0
2
4
6
month
Fraction=0.67
age bracket:  up to 39
Infe
ctions
ICU
0 3 6 9 12 15 18 21 24 27 30 33 36
0e+00
1e+07
2e+07
3e+07
0
2
4
6
month
age bracket:  up to 49
Infe
ctions
ICU
0 3 6 9 12 15 18 21 24 27 30 33 36
0e+00
1e+07
2e+07
3e+07
0
2
4
6
month
age bracket:  up to 59
Infe
ctions
ICU
0 3 6 9 12 15 18 21 24 27 30 33 36
0e+00
1e+07
2e+07
3e+07
0
2
4
6
month
age bracket:  up to 69
Infe
ctions
ICU
0 3 6 9 12 15 18 21 24 27 30 33 36
0e+00
1e+07
2e+07
3e+07
0
2
4
6
month
Fraction=1
age bracket:  up to 39
Infe
ctions
ICU
0 3 6 9 12 15 18 21 24 27 30 33 36
0e+00
1e+07
2e+07
3e+07
4e+07
0
2
4
6
month
age bracket:  up to 49
Infe
ctions
ICU
0 3 6 9 12 15 18 21 24 27 30 33 36
0e+00
1e+07
2e+07
3e+07
4e+07
5e+07
0
2
4
6
month
age bracket:  up to 59
Infe
ctions
ICU
0 3 6 9 12 15 18 21 24 27 30 33 36
0e+00
2e+07
4e+07
6e+07
0
3
6
9
12
month
age bracket:  up to 69
Figure 8: Scenarios for R0 = 2.4, very strict mitigations (90% reduction in transmission for groups subject
to mitigations). Scenarios which do not exceed the nominal ICU capacity by more than 50% are highlighted.
age bracket 80+70−79
60−69
50−59
40−49
30−39
20−29
10−19
0−9
Infe
ctions
ICU
0 3 6 9 12 15 18 21 24 27 30 33 36
0e+00
1e+07
2e+07
3e+07
0
2
4
6
month
Fraction=0.67
age bracket:  up to 39
Infe
ctions
ICU
0 3 6 9 12 15 18 21 24 27 30 33 36
0e+00
1e+07
2e+07
3e+07
0
2
4
6
month
age bracket:  up to 49
Infe
ctions
ICU
0 3 6 9 12 15 18 21 24 27 30 33 36
0e+00
1e+07
2e+07
3e+07
0
2
4
6
month
age bracket:  up to 59
Infe
ctions
ICU
0 3 6 9 12 15 18 21 24 27 30 33 36
0e+00
1e+07
2e+07
3e+07
0
2
4
6
month
age bracket:  up to 69
Infe
ctions
ICU
0 3 6 9 12 15 18 21 24 27 30 33 36
0e+00
1e+07
2e+07
3e+07
0
2
4
6
month
Fraction=1
age bracket:  up to 39
Infe
ctions
ICU
0 3 6 9 12 15 18 21 24 27 30 33 36
0e+00
1e+07
2e+07
3e+07
4e+07
0
2
4
6
month
age bracket:  up to 49
Infe
ctions
ICU
0 3 6 9 12 15 18 21 24 27 30 33 36
0e+00
2e+07
4e+07
6e+07
0.0
2.5
5.0
7.5
10.0
month
age bracket:  up to 59
Infe
ctions
ICU
0 3 6 9 12 15 18 21 24 27 30 33 36
0e+00
2e+07
4e+07
6e+07
0
5
10
month
age bracket:  up to 69
Figure 9: Scenarios for R0 = 2.4, strict mitigations (70% reduction in transmission for groups subject to
mitigations). Scenarios which do not exceed the nominal ICU capacity by more than 50% are highlighted.
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Figure 10: Scenarios for R0 = 2.4, moderate mitigations (50% reduction in transmission for groups subject
to mitigations). All of these scenarios exceed the nominal ICU capacity by more than 50%.
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Figure 11: Scenarios for R0 = 2.7, very strict mitigations (90% reduction in transmission for groups subject
to mitigations). Scenarios which do not exceed the nominal ICU capacity by more than 50% are highlighted.
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Figure 12: Scenarios for R0 = 2.7, strict mitigations (70% reduction in transmission for groups subject to
mitigations). Scenarios which do not exceed the nominal ICU capacity by more than 50% are highlighted.
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Figure 13: Scenarios for R0 = 2.7, moderate mitigations (50% reduction in transmission for groups subject
to mitigations). All of these scenarios exceed the nominal ICU capacity by more than 50%.
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Figure 14: Scenarios for R0 = 3.0, very strict mitigations (90% reduction in transmission for groups subject
to mitigations). Scenarios which do not exceed the nominal ICU capacity by more than 50% are highlighted.
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Figure 15: Scenarios for R0 = 3.0, strict mitigations (70% reduction in transmission for groups subject to
mitigations). Scenarios which do not exceed the nominal ICU capacity by more than 50% are highlighted.
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Figure 16: Scenarios for R0 = 3.0, moderate mitigations (50% reduction in transmission for groups subject
to mitigations). All of these scenarios exceed the nominal ICU capacity by more than 50%.
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